Obesity remains high in the US., but more states are showing progress, a new report finds

A new report indicates that the number of U.S. states with adult obesity rates of 35% or higher dropped for the first time in over a decade, from 23 states in 2023 to 19 in 2024, suggesting potential progress in public health. This improvement may be partly attributed to the wider use of obesity drugs like Wegovy and Zepbound, as well as increased nutrition assistance programs. However, this nascent progress is at risk due to recent federal funding cuts, staff layoffs, and program eliminations, which could impact future trends in healthcare spending and pharmaceutical market dynamics for obesity treatments.

Analysis

A recent report indicates a notable shift in U.S. obesity trends, with the number of states reporting adult obesity rates of 35% or higher decreasing from 23 in 2023 to 19 in 2024. This marks the first such decline in over a decade, offering an encouraging sign despite the overall U.S. obesity rate remaining high at approximately 40% of the population.

This nascent improvement is potentially attributable to factors such as the wider adoption of GLP-1 agonist drugs like Wegovy and Zepbound, alongside increased nutrition assistance programs implemented during the COVID-19 pandemic. However, experts caution that it is "too soon to call it a trend," emphasizing the preliminary nature of this progress.

Crucially, this potential progress faces significant headwinds from recent federal funding cuts, staff layoffs, and program eliminations targeting chronic disease prevention. While a U.S. Health and Human Services Department spokesman stated efforts are underway to "restructure public health programs" for "real prevention," these reductions could jeopardize sustained improvement.

The mixed sentiment and cautious tone surrounding this report underscore the fragility of these gains. The interplay between pharmaceutical innovation, public health initiatives, and fiscal policy will be critical in determining future obesity trends and their broader impact on healthcare expenditures.

Key Decisions for Investors

• Investors should closely monitor federal and state healthcare policy shifts, particularly regarding funding for chronic disease prevention and public health programs, as these directly influence long-term healthcare spending and market dynamics for related industries
• Pharmaceutical companies specializing in obesity treatments, such as GLP-1 agonists, warrant continued evaluation for demand sustainability, given their potential role in observed improvements, but also considering the broader policy risks
• Assess the durability of the reported obesity rate improvements, recognizing the 'mixed' sentiment and 'cautious' tone, and factor in the potential for reversals if public health infrastructure support diminishes